BR112020021812A2 - forma de dosagem, método para tratar uma doença, distúrbio, síndrome e/ou afecção em um paciente com necessidade do mesmo, e método para produzir uma forma de dosagem - Google Patents

forma de dosagem, método para tratar uma doença, distúrbio, síndrome e/ou afecção em um paciente com necessidade do mesmo, e método para produzir uma forma de dosagem Download PDF

Info

Publication number
BR112020021812A2
BR112020021812A2 BR112020021812-0A BR112020021812A BR112020021812A2 BR 112020021812 A2 BR112020021812 A2 BR 112020021812A2 BR 112020021812 A BR112020021812 A BR 112020021812A BR 112020021812 A2 BR112020021812 A2 BR 112020021812A2
Authority
BR
Brazil
Prior art keywords
dosage form
magnesium
threonate
day
disorder
Prior art date
Application number
BR112020021812-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Guosong Liu
Fei Mao
Jason Gregory WEINGER
Original Assignee
Neurocentria, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocentria, Inc. filed Critical Neurocentria, Inc.
Publication of BR112020021812A2 publication Critical patent/BR112020021812A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112020021812-0A 2018-04-25 2019-04-24 forma de dosagem, método para tratar uma doença, distúrbio, síndrome e/ou afecção em um paciente com necessidade do mesmo, e método para produzir uma forma de dosagem BR112020021812A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662756P 2018-04-25 2018-04-25
US62/662,756 2018-04-25
PCT/US2019/028903 WO2019209943A1 (en) 2018-04-25 2019-04-24 Magnesium threonate compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR112020021812A2 true BR112020021812A2 (pt) 2021-02-23

Family

ID=68291941

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020021812-0A BR112020021812A2 (pt) 2018-04-25 2019-04-24 forma de dosagem, método para tratar uma doença, distúrbio, síndrome e/ou afecção em um paciente com necessidade do mesmo, e método para produzir uma forma de dosagem

Country Status (9)

Country Link
US (2) US11717501B2 (https=)
EP (1) EP3784227A4 (https=)
JP (2) JP2021522344A (https=)
KR (1) KR20210005662A (https=)
CN (3) CN112384210A (https=)
AU (2) AU2019261406A1 (https=)
BR (1) BR112020021812A2 (https=)
CA (1) CA3098360A1 (https=)
WO (1) WO2019209943A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384210A (zh) 2018-04-25 2021-02-19 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途
MY197760A (en) 2020-06-01 2023-07-13 Celagenex Res India Pvt Ltd Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
JP7805352B2 (ja) * 2020-08-28 2026-01-23 ディーエフアイ ユーエスエー，エルエルシー Ｌ－キシロン酸からｌ－トレオン酸塩を生産する方法
CN114304610A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有苏糖酸镁的营养补充剂及其应用
WO2024232931A1 (en) * 2023-05-11 2024-11-14 Yon Doo Ough Apparatus and method for contact free delivery and administration of magnesium as a drug
CN119504413A (zh) * 2025-01-20 2025-02-25 浙江天启生化股份有限公司 一种l-苏糖酸镁合成方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
CN113143901A (zh) * 2007-03-22 2021-07-23 纽罗森特里亚股份有限公司 镁组合物及其用途
US8163301B2 (en) 2007-03-22 2012-04-24 Magceutics, Inc. Magnesium compositions and uses thereof for metabolic disorders
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
RU2607595C2 (ru) * 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
WO2017044486A1 (en) * 2015-09-11 2017-03-16 Neurocentria, Inc. Threonate compounds and methods of use thereof
CN105326855A (zh) * 2015-10-27 2016-02-17 南京大学 易吸收复合夹层式螯合镁钙片
CN105326955B (zh) * 2015-11-02 2019-04-12 北京市眼科研究所 一种治疗睑缘炎的组合物及其制备方法
US10617713B2 (en) * 2016-03-08 2020-04-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
CN107625776A (zh) * 2016-07-19 2018-01-26 无锡脑镁素生物医药科技有限公司 用于改善睡眠的镁组合物及其用途
CN106360734A (zh) * 2016-09-28 2017-02-01 张家港威胜生物医药有限公司 一种同时具有减肥和美容作用的组合物及其制备方法与用途
WO2018200885A1 (en) * 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
CN112384210A (zh) 2018-04-25 2021-02-19 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途

Also Published As

Publication number Publication date
CN120168449A (zh) 2025-06-20
JP2021522344A (ja) 2021-08-30
CN112384210A (zh) 2021-02-19
EP3784227A4 (en) 2022-03-02
AU2019261406A1 (en) 2020-12-17
US20240156761A1 (en) 2024-05-16
US11717501B2 (en) 2023-08-08
KR20210005662A (ko) 2021-01-14
AU2025201393A1 (en) 2025-03-20
WO2019209943A1 (en) 2019-10-31
CA3098360A1 (en) 2019-10-31
JP2025011238A (ja) 2025-01-23
US20190328689A1 (en) 2019-10-31
CN120241690A (zh) 2025-07-04
EP3784227A1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
BR112020021812A2 (pt) forma de dosagem, método para tratar uma doença, distúrbio, síndrome e/ou afecção em um paciente com necessidade do mesmo, e método para produzir uma forma de dosagem
JP2022522270A (ja) 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
ES2606463T3 (es) Combinación de formas de dosificación de levodopa/carbidopa de liberación inmediata y liberación controlada
NO336938B1 (no) Farmasøytisk sammensetning av vedvarende frigjøringsformulering av amfetaminer eller amfetaminsalter
CN109475510B (zh) 普瑞巴林的延长释放剂型
CN109223725A (zh) 用于以低的日剂量施用的含富马酸二甲酯的药物组合物
ES2408343A2 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
MXPA06002023A (es) Nueva formulacion de ropinirol.
JP2021506944A (ja) 持続放出ミドドリン塩酸塩組成物及び使用方法
BRPI0910572B1 (pt) Comprimido destinado a administração por via oral de um ou vários ingrediente(s) ativo e apto a garantir latência na liberação do ativo acrescido de posterior duplo mecanismo de liberação do referido ingrediente ativo, processo de preparação de um comprimido e micropartículas
JP2022518703A (ja) ホスホジエステラーゼ阻害剤を含有する放出調節錠剤製剤
JPS62501845A (ja) 制御放出塩化カリウム
JP2022522005A (ja) Ｔｂｎ、又はその塩もしくは水和物を含む薬物組成物及びその製造方法
WO2017101858A1 (zh) 环苄普林之延释剂型
WO2017084486A1 (zh) 简易制备结肠炎和克罗恩病用高载药量缓释制剂的方法
TW200800155A (en) Gastric retentive gabapentin dosage forms and methods for using same
CN101756981B (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
AU780505B2 (en) Sustained-release formulations for treating CNS-mediated disorders
JP2016539171A (ja) アセブロフィリン及び疎水性徐放性基剤を含む徐放性薬学組成物
ES2317450T3 (es) Formulacion de liberacion controlada de acido valproico y sus derivados.
CN110384669A (zh) 一种司美替尼及其衍生物的新剂型及制备方法
BR102023025187A2 (pt) Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral
WO2007056570A2 (en) Levodopa compositions
WO2025111679A1 (pt) Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral
WO2022133555A1 (pt) Composição farmacêutica sólida contendo vitamina d e sal de cálcio, método para tratar ou prevenir condições relacionadas a baixa ingestão e/ou maior necessidade de cálcio, uso da composição farmacêutica sólida e produto farmacêutico ou suplementar

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: NEUROCENTRIA, INC. (US)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]